Terazosin Hydrochloride

HCID 63016CAS 70024-40-7

기본 정보

표준 SMILES: COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O
InChIKey: NZMOFYDMGFQZLS-UHFFFAOYSA-N
분자식: C19H30ClN5O6
평균 분자량: 459.9 g/mol
단동위원소 질량: 459.18846136

개요

Terazosin Hydrochloride is the hydrochloride salt form of terazosin, a quinazoline derivative with adrenergic antagonistic property. Terazosin hydrochloride selectively inhibits alpha-1 adrenergic receptors, resulting in vasodilation leading to decreased peripheral vascular resistance and a reduced venous return to the heart as well as decreased urethral resistance, which potentially improving urine flow and symptoms related to benign prostatic hyperplasia. In addition, terazosin decreases low-density lipoproteins (LDL) and triglycerides while increasing the concentration of high-density lipoproteins (HDL).

이름 및 식별자

우선 이름: Terazosin Hydrochloride
IUPAC: [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;dihydrate;hydrochloride

이름 및 동의어

Terazosin hydrochloride dihydrateUrodieItrinHytracinAbbott-45975TEZRULYTerazosin hcl 2h20Terazosin (as hydrochloride)1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrateD32S14F082NSC-759168Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-, monohydrochloride, dihydrate

이름 더 보기

CHEBI:9446DTXCID5025493BenphRefChem:571796,7-dimethoxy-2-(4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl)quinazolin-4-amine hydrochloride dihydrateDTXSID7045493Terazosin Hydrochloride70024-40-7

데이터베이스 식별자

CAS: 70024-40-7
PubChem CID: 63016
DTXSID: DTXSID801366621
ChEMBL: CHEMBL1201091、CHEMBL3989562
UNII: D32S14F082

물성

구조 계산 물성

극성 표면적: 105 Å²
수소 결합 공여자 수: 4
수소 결합 수용자 수: 10
회전 가능 결합 수: 4
무거운 원자 수: 31
형식 전하: 0
복잡도: 544

실험 및 물리화학적 성질

Human Drugs · 2건

FDA approved drugs -> Active ingredient

안전 및 규제

독성 정보

Treatment · 1건

Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein bound; therefore, dialysis may not be of benefit. (L1712)

Health EffectsHypotension, palpitations, postural hypotension, syncope, peripheral edema, weight gain, dyspnea, nasal congestion/rhinitis, impotence.

Exposure RoutesOral. Essentially completely absorbed in man (90% bioavailability).

Toxicity Summary · 1건

Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia.

Signs and SymptomsAsthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity. Route of Elimination: Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces. Half Life: 12 hours

FDA Pharmacological Classification · 2건

TERAZOSIN HYDROCHLORIDE

Adrenergic alpha-Antagonists [MoA]; alpha-Adrenergic Blocker [EPC]

MeSH Pharmacological Classification · 2건

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

용도 및 제조

Uses · 1건

Terazosin is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin. The long-term effects of terazosin on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin tablets are also indicated for the treatment of hypertension. Terazosin tablets can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.